Jump to content

Draft:OM Pharma

From Wikipedia, the free encyclopedia
  • Comment: This article would be accepted onto Wikipedia if it had significant coverage by three independent, reliable sources. The only source provided that passes is the first source, the Le Temps article. Noah 💬 22:01, 30 October 2024 (UTC)



OM Pharma
Company typeSociété Anonyme
IndustryBiopharmaceutical
FoundedBarcelona, (1930)
HeadquartersGeneva, Switzerland
Area served
Worldwide
Key people
  • Roch Ogier (CEO)
  • Sandrine Bertrand (Chief Technical Officer)
  • Patricia Licata (Chief Human Resources & Communication Officer)
  • Laurent Perritaz (Chief Financial Officer)
  • Pascal Schumacher (Chief Commercial Officer)
  • Anna Thomas (Chief Scientific Officer)
Products
OM-89
OwnerEtienne Jornod (Executive Chairman & Co‑Owner)
Websitewww.ompharma.com

OM Pharma is a Swiss multinational biopharmaceutical company headquartered in Geneva.

OM Pharma was established in Barcelona in 1930 and relocated its headquarters to Geneva in 1937 under the leadership of Jean-René Ricard, a French pharmacist. In 2020, the company became part of Optimus Holding, led by Etienne Jornod, which announced plans for substantial investments in research and manufacturing capabilities.[1][2][3].

The company specializes in developing and commercializing bacterial lysate-based products designed to help prevent respiratory and urinary tract infections by enhancing the immune system. Its research pipeline includes future applications of lysates[4][5].

In 2021, OM Pharma received the Geneva Economy Award [6]. The independent jury recognized the company's economic and social policies, which prioritize long-term development and reinvestment of profits into research and development[7][8].

History

[edit]

Integration into CSL Vifor/Galenica

[edit]

IIn 1970, OM Pharma relocated its main operations to Meyrin, where the company continues to operate. In 2009, it was acquired by Galenica, a part of the Vifor Pharma Group[9][10][11].

Acquisition by Optimus Holding

[edit]

In 2020, OM Pharma became an independent entity again following its acquisition by Optimus Holding, led by former Vifor Pharma Executive Chairman Etienne Jornod[12]. As part of the transaction, Optimus Holding committed to investing over CHF 250 million to enhance the company’s manufacturing and research capabilities[13]. Since 2024, Roch Ogier has served as the company’s CEO[14][15].

Structure and subsidiaries

[edit]

OM Pharma employs over 400 people, with its global headquarters and biotech campus located in Meyrin, Geneva, and an affiliate in Villars-sur-Glâne, Fribourg[16].

The company also operates in Peru through an affiliate in Lima and maintains a sales force in Central America, covering Guatemala, El Salvador, Honduras, Nicaragua, Costa Rica, Panama, and the Dominican Republic[17][18]. Additionally, OM Pharma has a presence in Shanghai to support its business partners in the Asia-Pacific region[19][20].

Research areas and products

[edit]

OM Pharma specializes in the development of bacterial lysate products, including OM-85 and OM-89, which are manufactured at its facility in Meyrin, Geneva[21]. The company also markets small-molecule drugs for the treatment of vascular diseases worldwide[22].

Globally marketed products

[edit]
  • Broncho Vaxom® is an immunomodulator and bacterial lysate (OM-85) of 21 bacterial strains used for the prevention of recurrent respiratory tract infections[23]
  • Uro Vaxom® is an immunomodulator and bacterial lysate (OM-89) of 18 strains of Escherichia coli for the treatment and prevention of recurrent urinary tract infections.
  • Dicynone® (etamsylate) is indicated in the treatment of capillary haemorrhages of different origins such as heavy menstrual bleeding or surgeries affecting highly vascularised tissues.
  • Doxium® (calcium dobesilate) is used for the oral treatment of microangiopathies, signs of chronic venous insufficiency in the lower limbs, diabetic retinopathy and haemorrhoidal syndrome.

References

[edit]
  1. ^ "Interview avec Etienne Jornod | Board Talk". Deloitte Switzerland (in Swiss French). Retrieved 2024-10-30.
  2. ^ "Etienne Jornod achète une deuxième fois OM Pharma à Genève - Le Temps" (in French). 2020-09-18. ISSN 1423-3967. Retrieved 2024-10-30.
  3. ^ "Etienne Jornod, président d'OM Pharma à Genève: «Il ne faut pas baisser le prix des médicaments de façon linéaire» - Le Temps" (in French). 2024-12-13. ISSN 1423-3967. Retrieved 2024-12-18.
  4. ^ Leo (2022-02-17). "List of the 3 largest chemical companies from Geneva (Canton)". Research Germany. Retrieved 2024-10-30.
  5. ^ Ogier, Roch; Kherad, Omar; Balavoine, Michael (2025-01-22). "Le travail de l'industrie pharmaceutique reste largement méconnu". Rev Med Suisse (in Swiss French). 902: 116–118.
  6. ^ "OM Pharma Wins Geneva Economy Award". PharmExec. 2021-09-21. Retrieved 2024-11-13.
  7. ^ "La Gazette du LABORATOIRE - OM Pharma remporte le Prix 2021 de l'économie genevoise". www.gazettelabo.fr. Retrieved 2024-11-13.
  8. ^ Hernandez, Miguel (2021-09-21). "Le Prix 2021 de l'économie genevoise attribué à OM Pharma" (in French). Retrieved 2024-11-13.
  9. ^ "Galenica acquiert la société biotech OM Pharma - Le Temps" (in French). 2009-09-08. ISSN 1423-3967. Retrieved 2024-11-01.
  10. ^ BioAlps, Admin (2021-10-20). "BioAlps | 20 years of innovation | OM Pharma". BioAlps. Retrieved 2024-10-30.
  11. ^ "économie - L'entreprise compte 65 % de frontaliers parmi ses 200 collaborateurs. OM Pharma, rescapée genevoise de la pharmaceutique, a 80 ans". www.ledauphine.com (in French). Retrieved 2024-11-01.
  12. ^ "Etienne Jornod, président d'OM Pharma à Genève: «Il ne faut pas baisser le prix des médicaments de façon linéaire» - Le Temps" (in French). 2024-12-13. ISSN 1423-3967. Retrieved 2024-12-18.
  13. ^ PricewaterhouseCoopers. "Vifor Pharma Group announces successful sale of OM Pharma to Optimus Holding Ltd". PwC. Retrieved 2024-10-30.
  14. ^ "La Gazette du LABORATOIRE - OM Pharma nomme Roch Ogier au poste de CEO". www.gazettelabo.fr. Retrieved 2024-11-01.
  15. ^ Ogier, Roch; Kherad, Omar; Balavoine, Michael (2025-01-22). "Le travail de l'industrie pharmaceutique reste largement méconnu". Rev Med Suisse (in Swiss French). 902: 116–118.
  16. ^ "Redevenue indépendante, OM Pharma vise les Etats-Unis - Le Temps" (in French). 2024-12-13. ISSN 1423-3967. Retrieved 2024-12-18.
  17. ^ "OM Pharma situa su filial peruana como hub regional para Latinoamérica". PMFarma. Retrieved 2024-10-30.
  18. ^ GESTIÓN, NOTICIAS (2023-05-03). "Farmacéutica | OM Pharma sitúa hub regional en Perú, las razones detrás y negocios a la vista | ECONOMIA". Gestión (in Spanish). Retrieved 2024-11-01.
  19. ^ "Cartography of the Geneva Health Hub - Health field concerned - Pharmacy - OM Pharma". platform.genevahealthforum.com. Retrieved 2024-10-30.
  20. ^ "OM Pharma opens a new office in Shanghai - OM Pharma | OM Pharma". www.ompharma.com. Retrieved 2024-10-30.
  21. ^ "Economie romande. OM Pharma, perle industrielle genevoise, s'ouvre les portes de l'Amérique du Nord - Le Temps" (in French). 2007-06-14. ISSN 1423-3967. Retrieved 2024-11-01.
  22. ^ "Redevenue indépendante, OM Pharma vise les Etats-Unis - Le Temps" (in French). 2024-12-13. ISSN 1423-3967. Retrieved 2024-12-18.
  23. ^ Dang, A. T.; Pasquali, C.; Ludigs, K.; Guarda, G. (2017-03-06). "OM-85 is an immunomodulator of interferon-β production and inflammasome activity". Scientific Reports. 7 (1): 43844. Bibcode:2017NatSR...743844D. doi:10.1038/srep43844. ISSN 2045-2322. PMID 28262817.
Retrieved from "https://wiki.riteme.site/w/index.php?title=Draft:OM_Pharma&oldid=1272592392"